Page last updated: 2024-11-07

2,3-bis(palmitoyloxy)-2-propyl-1-palmitoylcysteine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,3-bis(palmitoyloxy)-2-propyl-1-palmitoylcysteine: intermediate for immunogen preparation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135926
SCHEMBL ID483613
MeSH IDM0188867

Synonyms (35)

Synonym
pam3cys-oh
unii-r3pdv16in3
r3pdv16in3 ,
l-cysteine, s-(2,3-bis((1-oxohexadecyl)oxy)propyl)-n-(1-oxohexadecyl)-
pam3-cys-oh, >=98.0% (tlc)
2,3-bis(palmitoyloxy)-2-propyl-1-palmitoylcysteine
87420-41-5
n-palmitoyl-2,3-bis(palmitoyloxy)-2-propylcysteine
(2r)-3-[2,3-di(hexadecanoyloxy)propylsulfanyl]-2-(hexadecanoylamino)propanoic acid
70512-46-8
palmitoyl-s-[2,3-bis(palmitoyloxy)-(2rs)-propyl]-l-cysteine
palmitoyl-cys((rs)-2,3-di(palmitoyloxy)-propyl)-oh
pam3-cys-oh
SCHEMBL483613
tripalmitoyl-s-glycerylcysteine, rs epimer
s-(2,3-bis(palmitoyloxy)propyl)-n-palmitoyl-l-cysteine
(2r)-2-palmitoylamino-3-((2,3-bis(palmitoyloxy)propyl)thio)propionic acid
hexadecanoic acid, 1-((((2r)-2-carboxy-2-((1-oxohexadecyl)amino)ethyl)thio)methyl)-1,2-ethanediyl ester
n-.alpha.-palmitoyl-s-(2,3-bis(palmitoyloxy)-(2rs)-propyl)-l-cysteine
hexadecanoic acid, 1,1'-(1-((((2r)-2-carboxy-2-((1-oxohexadecyl)amino)ethyl)thio)methyl)-1,2-ethanediyl) ester
J420.031D ,
AKOS030242690
mfcd00153468
palmitoyl-cys((rs)-2,3-di(palmitoyloxy)-propyl)-oh (pam3-l-cys-oh)
pamys-oh
CS-0201586
palmitoyl-s-[2,3-bis(palmitoyloxy)-(2rs)-propyl]-l-cysteine (pam-l-cys[(2,3-bis-pamo)pr]-oh)
(2r)-3-((2,3-bis(palmitoyloxy)propyl)thio)-2-palmitamidopropanoic acid
n-alpha-palmitoyl-s-(2,3-bis(palmitoyloxy)-(2rs)-propyl)-l-cysteine
Q27287752
DTXSID401007550
s-[2,3-bis(hexadecanoyloxy)propyl]-n-(1-hydroxyhexadecylidene)cysteine
hexadecanoic acid,1,1'-[1-[[[(2r)-2-carboxy-2-[(1-oxohexadecyl)amino]ethyl]thio]methyl]-1,2-ethanediyl]ester
STARBLD0000663
HY-W141789

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" In dose-response studies 50 micrograms Pam3Cys-Ser-(Lys)4 per mouse was the most effective dose with a long period of high antibody levels after the second booster."( The influence of various adjuvants on antibody synthesis following immunization with an hapten.
Erhard, M; Kellner, J; Lösch, U; Schranner, I, 1992
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (43)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (6.98)18.2507
2000's31 (72.09)29.6817
2010's9 (20.93)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.57

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.57 (24.57)
Research Supply Index3.85 (2.92)
Research Growth Index5.42 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.57)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.17%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other45 (97.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]